Immunological Approaches to The Pathogenesis and Treatment of Bronchiectasis

Authors

  • Hikmatov Jasur Safarovich Bukhara State Medical Institute, Republic of Uzbekistan, Bukhara

DOI:

https://doi.org/10.62480/tjms.2023.vol21.pp80-87

Keywords:

bronchiectasis, respiratory infections, inflammation

Abstract

Bronchiectasis is characterized by a constant and abnormal expansion of the airways of the lungs (bronchi) and/or a violation of the tone of the muscle layer of the bronchial wall due to inflammation, sclerosis, dystrophy, hypoplasia. Bronchiectasis is a very common disease that is the main cause of respiratory problems. A deficiency in the host's immune response to bacterial infection is considered to be the main condition for the development of bronchiectasis. In addition, many patients have no identifiable cause and are defined as having an idiopathic disease. This can lead to the development of a chronic respiratory tract infection and subsequent inflammation. Patients tend to have persistent disease despite aggressive use of antibiotics and optimal sputum clearance techniques. New therapies based on the manipulation of the immune response are becoming available and offer significant promise for the treatment of this condition

References

Ходош Э.М. Бронхоэктатическая болезнь: Учебное пособие для самостоятельной работы

пульмонологов, торакальных хирургов, фтизиатров, терапевтов и врачей общей практики [Текст]

/ Э.М. Ходош. — Х., 2018. — 71 с.: ил.

Weycker D., Hansen G. L., Seifer F. D. Prevalence and incidence of noncystic fibrosis bronchiectasis

among US adults in 2013. Chronic Respiratory Disease. 2016;14(4):377–384.

Polverino E., Cacheris W., Spencer C., Operschall E. In O'Donnell AE: Global burden of non-cystic

fibrosis bronchiectasis: A simple empidemiologic analysis. 2012.

Khikmatov, J. S., Khudaibergenov Sh. N., Khamdamov B. Z., Ismatov J. K. "Bronchiectasis (literature

review)." Scientific progress 2.7 (2021): 94-108.

Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and Economic Burden of Bronchiectasis. Clinical

Pulmonary Medicine. 2005;12(4):205-209

Hikmatov J.S. "Bronchiectasis disease: etiology, pathogenesis, modern diagnosis and treatment."

Новости образования: исследование в XXI веке 1.3 (2022): 1048-1064.

Martínez-García M. Á., Soler-Catalunã J. J., Sanz Y. D., et al. Factors associated with bronchiectasis in

patients with COPD. CHEST. 2011;140(5):1130–1137.

King PT. The Role of the Immune Response in the Pathogenesis of Bronchiectasis. Biomed Res Int.

;2018:6802637.

Redondo M., Keyt H., Dhar R., Chalmers J. D. Global impact of bronchiectasis and cystic fibrosis.

Breathe. 2016;12(3):222–235.

Quinti I., Soresina A., Spadaro G., et al. Long-term follow-up and outcome of a large cohort of patients

with common variable immunodeficiency. Journal of Clinical Immunology. 2007;27(3):308–316.

Pasteur M. C., Helliwell S. M., Houghton S. J., et al. An investigation into causative factors in patients

with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2000;162(4):1277–

Vendrell M., de Gracia J., Rodrigo M.-J., et al. Antibody production deficiency with normal IgG levels

in bronchiectasis of unknown etiology. CHEST. 2005;127(1):197–204.

Zimmer J., Andrès E., Donato L., Hanau D., Hentges F., de la Salle H. Clinical and immunological aspects

of HLA class I deficiency. QJM: Monthly Journal of the Association of Physicians. 2005;98(10)

Chalmers J. D., McHugh B. J., Doherty C., et al. Mannose-binding lectin deficiency and disease severity

in non-cystic fibrosis bronchiectasis: a prospective study. The Lancet Respiratory Medicine.

;1(3):224–232.

Paulson M. L., Freeman A. F., Holland S. M. Hyper IgE syndrome: An update on clinical aspects and the

role of signal transducer and activator of transcription 3. Current Opinion in Allergy and Clinical

Immunology. 2008;8(6):527–533.

Kearney P. J., Kershaw C. R., Stevenson P. A. Bronchiectasis in acute leukaemia. British Medical Journal.

;2(6091):857–859.

Knowles G. K., Stanhope R., Green M. Bronchiectasis complicating chronic lymphatic leukaemia with

hypogammaglobulinaemia. Thorax. 1980;35(3):217–218.

Chen L. W., McShane P. J., Karkowsky W., et al. De Novo Development of Bronchiectasis in Patients

With Hematologic Malignancy. CHEST. 2017;152(3):683–685.

Basnayake T. L., Morgan L. C., Chang A. B. The global burden of respiratory infections in indigenous

children and adults: A review. Respirology. 2017;22(8):1518–1528.

Chang A. B., Marsh R. L., Upham J. W., et al. Toward making inroads in reducing the disparity of lung

health in Australian indigenous and new zealand maori children. FrontPediatr. 2015;3:9

Singleton R., Morris A., Redding G., et al. Lewis C: Bronchiectasis in Alaska Native children: causes and

clinical courses. PediatrPulmonol. 2000;29(3):182–187.

Watt A. P., Brown V., Courtney J., et al. Neutrophil apoptosis, proinflammatory mediators and cell counts

in bronchiectasis. Thorax. 2004;59(3):231–236.

Whitters D., Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax.

;67(11):1006–1013.

Simpson J. L., Grissell T. V., Douwes J., Scott R. J., Boyle M. J., Gibson P. G. Innate immune activation

in neutrophilic asthma and bronchiectasis. Thorax. 2007;62(3):211–218.

Salvator H., Mahlaoui N., Catherinot E., et al. Pulmonary manifestations in adult patients with chronic

granulomatous disease. European Respiratory Journal. 2015;45(6):1613–1623.

Ho J. C., Tipoe G., Zheng L., et al. In vitro study of regulation of IL-6 production in bronchiectasis.

Respiratory Medicine. 2004;98(4):334–341.

Downloads

Published

2023-06-26

Issue

Section

Articles

How to Cite

Immunological Approaches to The Pathogenesis and Treatment of Bronchiectasis. (2023). Texas Journal of Medical Science, 21, 80-87. https://doi.org/10.62480/tjms.2023.vol21.pp80-87